Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (81-90 of 205) with videos related to

Pageof 21
Sort By:
Blood|June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsMin Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.
Haematologica|October 26, 2010
OCT-1 function varies with cell lineage but is not influenced by BCR-ABLJane R Engler, Andrew C W Zannettino, Charles G Bailey, et al.
Clinical Pharmacokinetics|December 21, 2016
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia PatientsDaniel T Barratt, Hannah K Cox, Andrew Menelaou, et al.
Blood|April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
The Journal of Clinical Investigation|August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah, Brian J Skaggs, Susan Branford, et al.
Haematologica|February 9, 2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialFrançois Guilhot, Timothy P Hughes, Jorge Cortes, et al.
Leukemia & Lymphoma|June 9, 2020
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Cancer Biology & Therapy|August 3, 2010
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivoCara K Fraser, Erin L Lousberg, Leigh R Guerin, et al.
Leukemia & Lymphoma|July 2, 2011
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysCarine Tang, Lisa Schafranek, Dale B Watkins, et al.
Experimental Hematology|December 6, 2008
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoCara K Fraser, Stephen J Blake, Kerrilyn R Diener, et al.
Pageof 21

Showing results (81-90 of 205) with videos related to

Sort By:
Pageof 21
Blood|June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsMin Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.
Haematologica|October 26, 2010
OCT-1 function varies with cell lineage but is not influenced by BCR-ABLJane R Engler, Andrew C W Zannettino, Charles G Bailey, et al.
Clinical Pharmacokinetics|December 21, 2016
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia PatientsDaniel T Barratt, Hannah K Cox, Andrew Menelaou, et al.
Blood|April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
The Journal of Clinical Investigation|August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah, Brian J Skaggs, Susan Branford, et al.
Haematologica|February 9, 2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialFrançois Guilhot, Timothy P Hughes, Jorge Cortes, et al.
Leukemia & Lymphoma|June 9, 2020
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Cancer Biology & Therapy|August 3, 2010
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivoCara K Fraser, Erin L Lousberg, Leigh R Guerin, et al.
Leukemia & Lymphoma|July 2, 2011
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysCarine Tang, Lisa Schafranek, Dale B Watkins, et al.
Experimental Hematology|December 6, 2008
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoCara K Fraser, Stephen J Blake, Kerrilyn R Diener, et al.
Pageof 21